Anabolic–Androgenic Steroid Abuse Impairs Fibrin Clot Lysis

Abstract

Abuse of anabolic–androgenic steroids (AASs) is suspected to increase the risk of cardiovascular disease (CVD) and cardiovascular mortality in otherwise healthy individuals. AAS abuse may increase the incidence of CVD by altering the hemostatic balance toward a procoagulant state. Studies on the effect of AAS abuse on the fibrinolytic system, however, have either demonstrated a profibrinolytic effect or no effect of AAS abuse, but the overall effect of AAS on fibrinolysis has not been addressed so far. This cross-sectional study investigated the effect of AAS on fibrin clot lysis, fibrin structure, and the hemostatic proteins, potentially affecting these measures in current and former AAS abusers and healthy age-matched controls. The study population consisted of 37 current and 33 former AAS abusers, along with 30 healthy age-matched controls. Fibrin clot lysis, fibrin structure properties, fibrinogen, coagulation factor XIII (FXIII) plasminogen, plasmin inhibitor, plasminogen activator inhibitor-1 (PAI-1), and thrombin activatable fibrinolysis inhibitor (TAFI) were determined. Fibrin clot lysis was significantly reduced in participants abusing AAS compared with former abusers and controls (p < 0.001). Plasma fibrinogen, plasminogen, and plasmin inhibitor were significantly increased in current abusers (p < 0.05). No significant differences were observed with respect to measures of fibrin structure properties, PAI-1, and TAFI (p > 0.05). In conclusion, AAS abuse depresses fibrin clot lysis. This effect is not associated with alterations in fibrin structure but is rather caused by increased plasma concentrations of fibrinogen, FXIII, and plasmin inhibitor. These findings suggest that AAS abuse may be associated with increased thrombotic disease.

Keywords

anabolic–androgenic steroids - fibrinolysis - fibrin clot structure - coagulation

Publikationsverlauf

Artikel online veröffentlicht:
05. Oktober 2020

• References

• 1 Pope Jr HG, Kanayama G, Athey A, Ryan E, Hudson JI, Baggish A. The lifetime prevalence of anabolic-androgenic steroid use and dependence in Americans: current best estimates. Am J Addict 2014; 23 (04) 371-377
• 2 Sagoe D, Molde H, Andreassen CS, Torsheim T, Pallesen S. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Ann Epidemiol 2014; 24 (05) 383-398
• 3 Angell P, Chester N, Green D, Somauroo J, Whyte G, George K. Anabolic steroids and cardiovascular risk. Sports Med 2012; 42 (02) 119-134
• 4 Baggish AL, Weiner RB, Kanayama G. et al. Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation 2017; 135 (21) 1991-2002
• 5 La Gerche A, Brosnan MJ. Cardiovascular effects of performance-enhancing drugs. Circulation 2017; 135 (01) 89-99
• 6 Rasmussen JJ, Schou M, Madsen PL. et al. Cardiac systolic dysfunction in past illicit users of anabolic androgenic steroids. Am Heart J 2018; 203: 49-56
• 7 Lippi G, Banfi G. Doping and thrombosis in sports. Semin Thromb Hemost 2011; 37 (08) 918-928
• 8 Thiblin I, Garmo H, Garle M. et al. Anabolic steroids and cardiovascular risk: a national population-based cohort study. Drug Alcohol Depend 2015; 152: 87-92
• 9 Chang S, Rasmussen JJ, Frandsen MN. et al. Procoagulant state in current and former anabolic androgenic steroid abusers. Thromb Haemost 2018; 118 (04) 647-653
• 10 Chang S, Münster AB, Gram J, Sidelmann JJ. Anabolic androgenic steroid abuse: the effects on thrombosis risk, coagulation, and fibrinolysis. Semin Thromb Hemost 2018; 44 (08) 734-746
• 11 Bouma BN, Mosnier LO. Thrombin activatable fibrinolysis inhibitor (TAFI)--how does thrombin regulate fibrinolysis?. Ann Med 2006; 38 (06) 378-388
• 12 Undas A, Ariëns RA. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 2011; 31 (12) e88-e99
• 13 Lisman T. Decreased plasma fibrinolytic potential as a risk for venous and arterial thrombosis. Semin Thromb Hemost 2017; 43 (02) 178-184
• 14 Rasmussen JJ, Selmer C, Østergren PB. et al. Former abusers of anabolic androgenic steroids exhibit decreased testosterone levels and hypogonadal symptoms years after cessation: a case-control study. PLoS One 2016; 11 (08) e0161208
• 15 Rasmussen JJ, Schou M, Selmer C. et al. Insulin sensitivity in relation to fat distribution and plasma adipocytokines among abusers of anabolic androgenic steroids. Clin Endocrinol (Oxf) 2017; 87 (03) 249-256
• 16 Rasmussen JJ, Schou M, Madsen PL. et al. Increased blood pressure and aortic stiffness among abusers of anabolic androgenic steroids: potential effect of suppressed natriuretic peptides in plasma?. J Hypertens 2018; 36 (02) 277-285
• 17 Bhasin S, Woodhouse L, Casaburi R. et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001; 281 (06) E1172-E1181
• 18 Skov J, Sidelmann JJ, Bladbjerg EM, Jespersen J, Gram J. Lysability of fibrin clots is a potential new determinant of stroke risk in atrial fibrillation. Thromb Res 2014; 134 (03) 717-722
• 19 Sjøland JA, Sidelmann JJ, Brabrand M. et al. Fibrin clot structure in patients with end-stage renal disease. Thromb Haemost 2007; 98 (02) 339-345
• 20 Carr ME, Gabriel DA. The effect of dextran 70 on the structure of plasma-derived fibrin gels. J Lab Clin Med 1980; 96 (06) 985-993
• 21 Carr Jr ME, Hermans J. Size and density of fibrin fibers from turbidity. Macromolecules 1978; 11 (01) 46-50
• 22 Sidelmann J. Contact Activation of the Fibrinolytic System in Human Blood [PhD dissertation]. Odense, Denmark: University of Southern Denmark; 1997: 83
• 23 Rijken DC, Uitte de Willige S. Inhibition of fibrinolysis by coagulation factor XIII. BioMed Res Int 2017; 2017: 1209676
• 24 Collet JP, Allali Y, Lesty C. et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006; 26 (11) 2567-2573
• 25 Glueck CJ, Freiberg R, Glueck HI, Tracy T, Stroop D, Wang Y. Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high lipoprotein(a), and therapy with Stanozolol. Am J Hematol 1995; 48 (04) 213-220
• 26 Kluft C, Preston FE, Malia RG. et al. Stanozolol-induced changes in fibrinolysis and coagulation in healthy adults. Thromb Haemost 1984; 51 (02) 157-164
• 27 Ledford MR, Horton A, Wang G, Brito M, Delgado L. Efficacy of danazol in a patient with congenital protein-S deficiency: paradoxical evidence for decreased platelet activation with increased thrombin generation. Thromb Res 1997; 87 (05) 473-482
• 28 Small M, McArdle BM, Lowe GD, Forbes CD, Prentice CR. The effect of intramuscular stanozolol on fibrinolysis and blood lipids. Thromb Res 1982; 28 (01) 27-36
• 29 Thorisdottir H, Evans JA, Schwartz HJ, Comp P, Haluschak J, Ratnoff OD. Some clotting factors in plasma during danazol therapy: free and total protein S, but not C4b-binding protein, are elevated by danazol therapy. J Lab Clin Med 1992; 119 (06) 698-701
• 30 Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med 2004; 34 (08) 513-554
• 31 Kahn NN, Sinha AK, Spungen AM, Bauman WA. Effects of oxandrolone, an anabolic steroid, on hemostasis. Am J Hematol 2006; 81 (02) 95-100